{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:30:03Z","timestamp":1793316603010,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"crossref","award":["03T-459"],"award-info":[{"award-number":["03T-459"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"crossref","award":["05T-726"],"award-info":[{"award-number":["05T-726"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health","award":["K05-DA0454"],"award-info":[{"award-number":["K05-DA0454"]}]},{"name":"Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health","award":["P50-DA18827"],"award-info":[{"award-number":["P50-DA18827"]}]},{"name":"Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health","award":["U01-MH79639"],"award-info":[{"award-number":["U01-MH79639"]}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.pnpbp.2013.02.015","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T11:37:25Z","timestamp":1362483445000},"page":"200-206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":356,"special_numbering":"C","title":["Free radicals, antioxidant defense systems, and schizophrenia"],"prefix":"10.1016","volume":"46","author":[{"given":"Jing Qin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2013.02.015_bb0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/clinchem\/32.5.805","article-title":"Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients","volume":"32","author":"Abdalla","year":"1986","journal-title":"Clin Chem"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","article-title":"Vitamin E treatment of tardive dyskinesia","volume":"150","author":"Adler","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0006-3223(97)00027-9","article-title":"Long-term treatment effects of vitamin E for tardive dyskinesia","volume":"43","author":"Adler","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pnpbp.2004.10.014","article-title":"Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia","volume":"29","author":"Akyol","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1515\/CCLM.2000.201","article-title":"Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients","volume":"38","author":"Altuntas","year":"2000","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00441-004-0976-5","article-title":"Redox imbalance","volume":"318","author":"Berg","year":"2004","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2005.05.019","article-title":"The many faces of nitric oxide in schizophrenia","volume":"78","author":"Bernstein","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","article-title":"Oxidative stress in schizophrenia: an integrated approach","volume":"35","author":"Bitanihirwe","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0045","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0006-3223(87)90069-2","article-title":"Glutathione peroxidase and CT scan abnormalities in schizophrenia","volume":"22","author":"Buckman","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(90)90103-C","article-title":"Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables","volume":"31","author":"Buckman","year":"1990","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/ajp.151.3.327","article-title":"The deficit syndrome","volume":"151","author":"Carpenter","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0060","first-page":"237","article-title":"Oxidative stress in schizophrenia \u2014 focusing on the main markers","volume":"23","author":"Ciobica","year":"2011","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00004714-198210000-00010","article-title":"Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?","volume":"2","author":"Crow","year":"1982","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bss0610001","article-title":"Oxidative stress: the paradox of aerobic life","volume":"61","author":"Davies","year":"1995","journal-title":"Biochem Soc Symp"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/15622970701361263","article-title":"Isoprostenes as indicators of oxidative stress in schizophrenia","volume":"10","author":"Dietrich-Muszalska","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0080","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","article-title":"Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo","volume":"12","author":"Do","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1176\/ajp.149.6.773","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"149","author":"Egan","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0090","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.pnpbp.2005.11.009","article-title":"Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine","volume":"30","author":"Gama","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1461145710000805","article-title":"Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders","volume":"14","author":"Gawryluk","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0100","first-page":"2449","article-title":"Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses","volume":"6","author":"Golse","year":"1977","journal-title":"Nouv Presse Med"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0105","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/01.ATV.20.10.2175","article-title":"Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology","volume":"20","author":"Griendling","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tibs.2006.07.005","article-title":"Phagocyte-derived reactive species: salvation or suicide?","volume":"31","author":"Halliwell","year":"2006","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1042\/BST0351147","article-title":"Biochemistry of oxidative stress","volume":"35","author":"Halliwell","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.mp.4000789","article-title":"Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia","volume":"6","author":"Herken","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.pnpbp.2006.12.019","article-title":"Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population","volume":"31","author":"Hitzeroth","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1192\/bjp.100.418.29","article-title":"Schizophrenia; a new approach. II. Result of a year's research","volume":"100","author":"Hoffer","year":"1954","journal-title":"J Ment Sci"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0140","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0893-133X(99)00156-6","article-title":"Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia","volume":"23","author":"Hori","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/10408448709089856","article-title":"Lipid peroxidation and mechanisms of toxicity","volume":"18","author":"Horton","year":"1987","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0150","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.pnpbp.2008.08.013","article-title":"Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients","volume":"32","author":"Kang","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0155","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/01926230290166724","article-title":"Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification","volume":"30","author":"Kohen","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02970132","article-title":"H2O2-induced higher order chromatin degradation: a novel mechanism of oxidative genotoxicity","volume":"28","author":"Konat","year":"2003","journal-title":"J Biosci"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cbf.940","article-title":"Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder","volume":"20","author":"Kuloglu","year":"2002","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0170","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0028-3908(03)00314-9","article-title":"Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats","volume":"45","author":"Lau","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2008.06.005","article-title":"Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls","volume":"104","author":"Lee","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0180","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.pnpbp.2011.03.001","article-title":"Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0185","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.pnpbp.2010.03.026","article-title":"Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients","volume":"34","author":"Liu","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0190","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1089\/ars.2000.2.4-851","article-title":"Redox control of protein degradation","volume":"2","author":"Lockwood","year":"2000","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ng1071","article-title":"Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease","volume":"33","author":"Lohmueller","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0200","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archpsyc.1991.01810360061009","article-title":"Oxygen radicals and neuropsychiatric illness. Some speculations","volume":"48","author":"Lohr","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0205","first-page":"159","article-title":"Free radical involvement in neuropsychiatric illnesses","volume":"31","author":"Lohr","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0210","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/schbul\/14.2.291","article-title":"Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms","volume":"14","author":"Lohr","year":"1988","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0220","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0006-3223(90)90490-S","article-title":"Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia","volume":"28","author":"Lohr","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0225","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0006-3223(97)00282-5","article-title":"Elevated plasma lipid peroxides at the onset of nonaffective psychosis","volume":"43","author":"Mahadik","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0230","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0278-5846(00)00181-0","article-title":"Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia","volume":"25","author":"Mahadik","year":"2001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0235","doi-asserted-by":"crossref","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","article-title":"Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study","volume":"3","author":"Matsuzawa","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0240","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1192\/bjp.167.5.610","article-title":"The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects","volume":"167","author":"McCreadie","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0245","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-11-26","article-title":"Reduced antioxidant defense in early onset first-episode psychosis: a case\u2013control study","volume":"11","author":"Mico","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0250","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0891-5849(90)90148-C","article-title":"Transition metals as catalysts of \u201cautoxidation\u201d reactions","volume":"8","author":"Miller","year":"1990","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0255","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.1993.01820210057007","article-title":"Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study","volume":"50","author":"Morgenstern","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0260","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0920-9964(95)00048-8","article-title":"Impaired antioxidant defense at the onset of psychosis","volume":"19","author":"Mukerjee","year":"1996","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008877-200305000-00010","article-title":"Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine","volume":"14","author":"Nel","year":"2003","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0270","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1017\/S1461145707008401","article-title":"Oxidative stress in psychiatric disorders: evidence base and therapeutic implications","volume":"11","author":"Ng","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0275","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0891-5849(01)00724-9","article-title":"Reactive oxygen species, antioxidants, and the mammalian thioredoxin system","volume":"31","author":"Nordberg","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0280","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neulet.2010.05.088","article-title":"Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics","volume":"479","author":"Padurariu","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0022-3956(02)00048-1","article-title":"Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain","volume":"37","author":"Parikh","year":"2003","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00004850-199300830-00003","article-title":"Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment","volume":"8","author":"Peet","year":"1993","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0295","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/jcp.46.9.861","article-title":"Increased pentane and carbon disulfide in the breath of patients with schizophrenia","volume":"46","author":"Phillips","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0300","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jpsychires.2006.01.011","article-title":"Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain","volume":"41","author":"Pillai","year":"2007","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-244X-11-124","article-title":"Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients","volume":"11","author":"Raffa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0165-1781(03)00220-8","article-title":"Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients","volume":"121","author":"Ranjekar","year":"2003","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0315","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1089\/ars.2010.3571","article-title":"Antioxidant therapeutics for schizophrenia","volume":"15","author":"Reddy","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0952-3278(96)90143-X","article-title":"Free radical pathology in schizophrenia: a review","volume":"55","author":"Reddy","year":"1996","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0006-3223(91)90298-Z","article-title":"Enzymes of the antioxidant defense system in chronic schizophrenic patients","volume":"30","author":"Reddy","year":"1991","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0330","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0920-9964(02)00407-3","article-title":"Reduced plasma antioxidants in first-episode patients with schizophrenia","volume":"62","author":"Reddy","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0335","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.pnpbp.2007.03.008","article-title":"Oxidative\u2013antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment","volume":"31","author":"Sarandol","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0340","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00041444-200409000-00012","article-title":"No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia","volume":"14","author":"Shinkai","year":"2004","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0345","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.psychres.2004.06.023","article-title":"Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia","volume":"141","author":"Shinkai","year":"2006","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0350","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00726-003-0011-2","article-title":"Free radical-mediated oxidation of free amino acids and amino acid residues in proteins","volume":"25","author":"Stadtman","year":"2003","journal-title":"Amino Acids"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0355","first-page":"103","article-title":"Glutathione peroxidase activity in the blood in chronic schizophrenia","volume":"29","author":"Stoklasova","year":"1986","journal-title":"Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0360","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0006-3223(90)90061-6","article-title":"Vitamin C status in chronic schizophrenia","volume":"28","author":"Suboticanec","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0365","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4001563","article-title":"Phenotype of schizophrenia: a review and formulation","volume":"10","author":"Tamminga","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0370","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1089-8603(02)00126-X","article-title":"Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain","volume":"7","author":"Tarazi","year":"2002","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0375","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10334-005-0012-0","article-title":"Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia","volume":"18","author":"Terpstra","year":"2005","journal-title":"MAGMA"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0380","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/ajp.155.9.1207","article-title":"Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia","volume":"155","author":"Tsai","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0385","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0390","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s005990050063","article-title":"An update on the role of free radicals and antioxidant defense in human disease","volume":"29","author":"Vendemiale","year":"1999","journal-title":"Int J Clin Lab Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0395","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000239684","article-title":"A defect in the antioxidant defense system in schizophrenia","volume":"60","author":"Virit","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0400","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0405","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.nbd.2008.11.018","article-title":"Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation","volume":"33","author":"Wood","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0410","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2011.08.018","article-title":"Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms","volume":"36","author":"Wu","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0415","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1017\/S0033291797005114","article-title":"Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia","volume":"27","author":"Yamada","year":"1997","journal-title":"Psychol Med"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0420","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1089\/ars.2010.3603","article-title":"Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view","volume":"15","author":"Yao","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0425","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1089\/ars.2010.3646","article-title":"Oxidative stress in schizophrenia: pathogenetic and therapeutic implications","volume":"15","author":"Yao","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0430","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-3956(98)00028-4","article-title":"Effects of haloperidol on antioxidant defense system enzymes in schizophrenia","volume":"32","author":"Yao","year":"1998","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(98)00030-9","article-title":"Reduced status of plasma total antioxidant capacity in schizophrenia","volume":"32","author":"Yao","year":"1998","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0440","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-1781(98)00051-1","article-title":"Reduced level of plasma antioxidant uric acid in schizophrenia","volume":"80","author":"Yao","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0445","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0006-3223(98)00184-X","article-title":"Human plasma glutathione peroxidase and symptom severity in schizophrenia","volume":"45","author":"Yao","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0450","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-1781(00)00230-4","article-title":"Abnormal age-related changes of plasma antioxidant proteins in schizophrenia","volume":"97","author":"Yao","year":"2000","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0455","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","article-title":"Altered glutathione redox state in schizophrenia","volume":"22","author":"Yao","year":"2006","journal-title":"Dis Markers"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0460","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pnpbp.2009.09.020","article-title":"Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes","volume":"34","author":"Zai","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0465","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-1781(02)00303-7","article-title":"Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms","volume":"117","author":"Zhang","year":"2003","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0470","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00004714-200304000-00004","article-title":"The effect of risperidone treatment on superoxide dismutase in schizophrenia","volume":"23","author":"Zhang","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0475","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.schres.2005.10.011","article-title":"Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics","volume":"81","author":"Zhang","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0480","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4088\/JCP.v68n0513","article-title":"Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia","volume":"68","author":"Zhang","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0485","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.schres.2009.05.016","article-title":"The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients","volume":"113","author":"Zhang","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0490","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11427-010-0013-8","article-title":"A meta-analysis of oxidative stress markers in schizophrenia","volume":"53","author":"Zhang","year":"2010","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0495","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2013.02.015_bb0500","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.neuropharm.2011.12.014","article-title":"Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia","volume":"62","author":"Zhang","year":"2012","journal-title":"Neuropharmacology"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584613000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T05:49:28Z","timestamp":1595483368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584613000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":100,"alternative-id":["S0278584613000493"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.02.015","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Free radicals, antioxidant defense systems, and schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2013.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}